Tag: Adalimumab

Recent advances in efficacy and safety evaluation of adalimumab in non-infectious uveitis

Authors: Guo Qi,  Wang Yandong DOI: 10.3760/cma.j.cn115989-20210705-00394 Published 2023-07-10 Cite as Chin J Exp Ophthalmol, 2023, 41(7): 708-712. Abstract                               [Download PDF] [Read Full Text] Non-infectious uveitis (NIU) is a serious sight-threatening disease caused by chronic inflammation and its complications.First-line treatment of NIU […]

Uveitis complicated with systemic tuberculosis associated with inappropriate adalimumab therapy: two case reports

Authors: Sun Ludan,  Zhu Jie,  Zhu Jun,  Yu Jing,  Chen Fang DOI: 10.3760/cma.j.cn115989-20220506-00196 Published 2022-08-10 Cite as Chin J Exp Ophthalmol, 2022, 40(8): 723-724. [View PDF] [Read Full Text] Contributor Information Sun Ludan Department of Ophthalmology, Northern Jiangsu People’s Hospital of Jiangsn Province, Yangzhou 225001, China Zhu Jie Department of Ophthalmology, Northern Jiangsu People’s Hospital of Jiangsn […]

Pay attention to the risk of infection and tumor progression during application of TNF-α inhibitors in uveitis

Authors: Chi Ying,  Yang Liu DOI: 10.3760/cma.j.cn115989-20211020-00571 Published 2021-11-10 Cite asChin J Exp Ophthalmol, 2021, 39(11): 929-932. Abstract                              [View PDF] [Read Full Text] Adalimumab, one of the tumor necrosis factor-α (TNF-α) inhibitors, has been approved as a therapeutic drug for non-infectious intermediate, posterior and pan-uveitis […]